Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice

被引:14
|
作者
Huo, Yuqi [1 ]
Wan, Xin [1 ]
Ling, Tong [1 ]
Wu, Jie [1 ]
Wang, Zejun [1 ]
Meng, Shengli [1 ]
Shen, Shuo [1 ]
机构
[1] Wuhan Inst Biol Prod Co Ltd, Wuhan, Peoples R China
关键词
Norovirus; Sydney-2012-like strain; Immune response; Adjuvants; VIRUS-LIKE PARTICLES; GROUP ANTIGEN RECEPTORS; CAPSID PROTEIN FORMS; P-DOMAIN; NORWALK; STRAIN; CELLS; NOMENCLATURE; BINDS; RNA;
D O I
10.1016/j.molimm.2015.09.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The newly emerged Norovirus (NoV) Sydney 2012 strain has been sweeping all over the world, causing acute non-bacterial gastroenteritis in adults and children. Due to a lack of cell culture system, virus like particles (VLPs) has been assembled and used as vaccine candidates in preclinical and clinical studies. Expression of the major capsid protein of NoVs using recombinant baculovirus expression system in Sf9 cells leads to formation of VLPs that are morphologically and antigenically similar to true virions. In this study, VLPs were successfully produced using the VP1 of Sydney-2012-like strain and its immunogenicity was evaluated by different routes and its capability in inducing mucosal immune responses in the presence and absence of adjuvants in BALB/c mice. Administration of NoV VLPs in the presence of Al(OH)(3) or monophosphoryl lipid A (MPL-A) led to high titers of VLP-specific IgG antibodies. Administration of VLPs orally in the presence of cholera toxin subunit B (CTB) didn't enhance mucosa( immune response as less fecal IgA positive mice were observed when compared with those given VLPs only. Our study represents the first immunogenicity study of VLPs derived from current pandemic Sydney 2012 strain and which might have implications in the development of NoVs vaccine in china. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:367 / 372
页数:6
相关论文
共 50 条
  • [31] Epidemiologic characteristics of outbreaks of three norovirus genotypes (GII.2, GII.17 and GII.4 Sydney) in Guangzhou, China, from 2012 to 2018
    Wang, H.
    Wang, D. H.
    Chen, C.
    Lu, Y.
    Li, M. X.
    Li, T. G.
    Zhang, Z. B.
    Yang, Z. C.
    EPIDEMIOLOGY AND INFECTION, 2019, 147
  • [32] High prevalence of norovirus GII.4 Sydney among children with acute gastroenteritis in Bangladesh, 2018-2021
    Sharif, Nadim
    Ahmed, Shamsun Nahar
    Sharif, Nazmul
    Alzahrani, Khalid J.
    Alsuwat, Meshari A.
    Alzahrani, Fuad M.
    Khandaker, Shamim
    Monifa, Nuzhat Haque
    Okitsu, Shoko
    Parvez, Anowar Khasru
    Ushijima, Hiroshi
    Dey, Shuvra Kanti
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2023, 16 (07) : 1015 - 1022
  • [33] Epidemiology and molecular characteristics of norovirus GII.4 Sydney outbreaks in Taiwan, January 2012-December 2013
    Wu, Fang-Tzy
    Chen, Hsieh-Cheng
    Yen, Catherine
    Wu, Ching-Yi
    Katayama, Kazuhiko
    Park, YoungBin
    Hall, Aron J.
    Vinje, Jan
    Huang, Jason C.
    Wu, Ho-Sheng
    JOURNAL OF MEDICAL VIROLOGY, 2015, 87 (09) : 1462 - 1470
  • [34] Use of rabbit antibodies raised against Norovirus GII.4 virus-like particles for diagnosis of Norovirus infection
    Kulkarni, Ruta
    Lole, Kavita
    Chitambar, Shobha D.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2017, 146 : 788 - 790
  • [35] Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus
    Koho, Tiia
    Huhti, Leena
    Blazevic, Vesna
    Nurminen, Kirsi
    Butcher, Sarah J.
    Laurinmaki, Pasi
    Kalkkinen, Nisse
    Ronnholm, Gunilla
    Vesikari, Timo
    Hytonen, Vesa P.
    Kulomaa, Markku S.
    JOURNAL OF VIROLOGICAL METHODS, 2012, 179 (01) : 1 - 7
  • [36] Gastroenteritis outbreak at a health function caused by an emerging recombinant strain of Norovirus GII.P16/GII.4 Sydney 2012, Australia
    Jones, B. J.
    Flint, J.
    Collins, J.
    White, P. A.
    Lun, J. H.
    Durrheim, D. N.
    EPIDEMIOLOGY AND INFECTION, 2018, 146 (08): : 970 - 971
  • [37] Genotype distribution of norovirus around the emergence of Sydney_2012 and the antigenic drift of contemporary GII.4 epidemic strains
    Zhang, Jun
    Shen, Zhen
    Zhu, Zhaoqin
    Zhang, Wanju
    Chen, Huifen
    Qian, Fangxing
    Chen, Haili
    Wang, Gang
    Wang, Moying
    Hu, Yunwen
    Yuan, Zhenghong
    JOURNAL OF CLINICAL VIROLOGY, 2015, 72 : 95 - 101
  • [38] Conformational Occlusion of Blockade Antibody Epitopes, a Novel Mechanism of GII.4 Human Norovirus Immune Evasion
    Lindesmith, Lisa C.
    Mallory, Michael L.
    Debbink, Kari
    Donaldson, Eric F.
    Brewer-Jensen, Paul D.
    Swann, Excel W.
    Sheahan, Timothy P.
    Graham, Rachel L.
    Beltramello, Martina
    Corti, Davide
    Lanzavecchia, Antonio
    Baric, Ralph S.
    MSPHERE, 2018, 3 (01):
  • [39] Persistence of the Immune Response to an Intramuscular Bivalent (GI.1/GII.4) Norovirus Vaccine in Adults
    Leroux-Roels, Geert
    Atmar, Robert L.
    Cramer, Jakob P.
    Escudero, Ian
    Borkowski, Astrid
    VACCINES, 2025, 13 (01)
  • [40] Analysis of early strains of the norovirus pandemic variant GII.4 Sydney 2012 identifies mutations in adaptive sites of the capsid protein
    Giammanco, G. M.
    De Grazia, S.
    Terio, V.
    Lanave, G.
    Catella, C.
    Bonura, F.
    Saporito, L.
    Medici, M. C.
    Tummolo, F.
    Calderaro, A.
    Banyai, K.
    Hansman, G.
    Martella, V.
    VIROLOGY, 2014, 450 : 355 - 358